Valuation
- Market cap
- —
- Revenue TTM
- $729,472,000
- Net income TTM
- $-5,067,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- -3.23%
- Debt to equity
- 1.40
Trading
- Volume
- 100
- Avg volume
- 728
- Day's range
- $1.29 – $1.29
- Shares out
- —
- Stochastic %K
- 8%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also...
Show more
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- Phone
- 403-777-1519
- Website
- https://innocanpharma.com
- Address
- 1015, 926 – 5 Avenue SW, Calgary, Canada
Latest news
No headlines yet.
